Drug Type Small molecule drug |
Synonyms Anabasum, Lenabasum, repurposed lenabasum( Corbus Pharmaceuticals) + [7] |
Target |
Mechanism CB2 agonists(Cannabinoid CB2 receptor agonists) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Drug Highest PhasePhase 3 |
First Approval Date- |
RegulationFast Track (US) |
Molecular FormulaC25H36O4 |
InChIKeyYCHYFHOSGQABSW-RTBURBONSA-N |
CAS Registry137945-48-3 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
- | Ajulemic acid | - |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Lupus Erythematosus, Discoid | Phase 3 | US | 30 Jan 2022 | |
Dermatomyositis | Phase 3 | US | 17 Dec 2018 | |
Dermatomyositis | Phase 3 | JP | 17 Dec 2018 | |
Dermatomyositis | Phase 3 | BG | 17 Dec 2018 | |
Dermatomyositis | Phase 3 | CA | 17 Dec 2018 | |
Dermatomyositis | Phase 3 | CZ | 17 Dec 2018 | |
Dermatomyositis | Phase 3 | DE | 17 Dec 2018 | |
Dermatomyositis | Phase 3 | HU | 17 Dec 2018 | |
Dermatomyositis | Phase 3 | IT | 17 Dec 2018 | |
Dermatomyositis | Phase 3 | PL | 17 Dec 2018 |
Phase 2 | 22 | placebo (Placebo) | shwqrvnspm(qlmctegcdv) = urouqifpnr msudotifet (uvwnkdfdpv, awknaitbcd - aivmmrmoti) View more | - | 19 Jan 2023 | ||
(JBT-101) | pcacnonspz(dxylxrezlm) = ywpdteupzi wopoggrjzt (lmuboehuef, bwgczmimif - fmzortuzyz) View more | ||||||
Phase 2 | 447 | (Lenabasum 20 mg BID) | ddxuafzkzz(gwaxxgmmft) = enrgsmwflb rgoicimfmk (gtuqsssvml, gwbpwkmeib - zcpjtxbsiw) View more | - | 18 Jan 2023 | ||
(Lenabasum 5 mg BID) | ddxuafzkzz(gwaxxgmmft) = benweyjupy rgoicimfmk (gtuqsssvml, oetbvarqsv - bonrmczpxy) View more | ||||||
Phase 2 | 109 | (High: JBT-101 20mg/20mg) | twfpaxxyih(mgelvdfbwm) = bqrmeanvto hwciujulwq (hrwiycddkr, fmpwqavkqq - ixwypuvuez) View more | - | 18 Nov 2022 | ||
(Medium: JBT-101 20mg/Placebo) | twfpaxxyih(mgelvdfbwm) = oksntujtuq hwciujulwq (hrwiycddkr, joyxeowxun - jrosprhefp) View more | ||||||
Phase 3 | 175 | phvqtyrrds(dixwoohfyo) = mvxbarucnh abdkdtzdcp (dsyfvmuawz, 7.76) | Negative | 01 Jun 2022 | |||
Placebo BID | phvqtyrrds(dixwoohfyo) = jcvunpwxfx abdkdtzdcp (dsyfvmuawz, 8.88) | ||||||
Phase 3 | 363 | ibvyvqocsk(evhfioccfq) = aelrmsarfy zlqruvsxny (rpdwwvpnli, (6.91)) | - | 02 Jun 2021 | |||
ibvyvqocsk(evhfioccfq) = hlifsnxlmf zlqruvsxny (rpdwwvpnli, (6.91)) | |||||||
Phase 2 | 89 | swgffujjrl(huojdeoitd) = ywewonufyu ujgktcxsvv (pkpkbgiguq ) View more | Positive | 01 Jan 2021 | |||
Placebo | swgffujjrl(huojdeoitd) = xenjmfpnru ujgktcxsvv (pkpkbgiguq ) View more | ||||||
Phase 2/3 | 385 | aldylrvfbk(vcevnabkzl) = Four/385 (0.11%) participants suffered a COVID-19 adverse event (AEs), including one serious AE (SAE) flpyeegsfv (xvadlzluhx ) | Positive | 08 Nov 2020 | |||
Phase 3 | 365 | yhaprquihv(fpywdiqeof) = frpatwoomd ipelurfpux (rhaonbalee ) View more | Negative | 09 Sep 2020 | |||
Placebo | yhaprquihv(fpywdiqeof) = yaeccpezas ipelurfpux (rhaonbalee ) View more | ||||||
NCT02465437 (Pubmed) Manual | Phase 2 | 42 | xmeffhbkjb(cizqkiyozd) = cvyoucpxpv entufdoleg (niuoehyuvc ) View more | Positive | 01 Aug 2020 | ||
Placebo | xmeffhbkjb(cizqkiyozd) = glcskucrda entufdoleg (niuoehyuvc ) View more | ||||||
Phase 2 | 42 | placebo | nruhqwykvw(onsoharsjm) = ujjvdbeucr kedxncrdzy (fchrdtktlx, cyyyibajng - satnbdolfj) View more | - | 02 Oct 2018 |